Estrella Immunopharma, Inc. — fact timeline

Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella Biopharma, Inc. at no interest maturing payable in full upon the consummation of the Company's business combination.

“Pursuant to the Merger Agreement, Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by April 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. incurred loan of $50,000 with Tradeup INC. at no interest.

“On March 3, 2023, TradeUP Acquisition Corp. (the “Company”) issued an unsecured promissory note (the “Promissory Note”) in the amount of $50,000 to Tradeup INC., one of the founders of the Company.”

Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella Biopharma, Inc. at no interest maturing upon the consummation of the Company's business combination.

“Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by March 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. incurred loan of $50,000 with TradeUP Acquisition Sponsor LLC at bear no interest maturing payable in full upon the consummation of the Company's business combination.

“On January 19, 2023, the Company issued an unsecured promissory note (the “Sponsor Note”) in the amount of $50,000 to TradeUP Acquisition Sponsor LLC, one of its sponsors (the “Sponsor”) to evidence a deposit that the Sponsor provided to the Company to pay its certain operating expenses.”

Estrella Immunopharma, Inc.: Amended certificate of incorporation to extend the date for completing a business combination from January 19, 2023 to July 19, 2023 (effective 2022-12-29).

“At the Special Meeting, the stockholders of the Company also approved the proposal to amend the Company’s amended and restated certificate of incorporation (the “Charter”) to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations of the Company if the Company has not completed a business combination would similarly be extended (the “Extension Proposal”).”

Estrella Immunopharma, Inc. amended Amendment to Investment Management Trust Agreement with Wilmington Trust, National Association (effective 2022-12-29).

“a special meeting of stockholders (the “Special Meeting”), where the stockholders of the Company approved the Company to, among others, amend the Investment Management Trust Agreement dated July 14, 2021 (the “Trust Agreement”), by and between the Company and Wilmington Trust, National Association (the “Trustee”) to extend the liquidation date from January 19, 2023 to July 19, 2023 .”

Estrella Immunopharma, Inc. shareholders approved The Auditor Appointment Proposal The stockholders ratified the engagement of Marcum LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-12-22 meeting.

“On December 22, 2022, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2022 annual meeting of stockholders (the “Special Meeting”). On November 30, 2022, the record date for the Special Meeting, there were 5,849,700 shares of common stock of the Company entitled to be voted at the Special Meeting, approximately 74.89% of which were represented in person or by proxy at the special meeting. The final results for each of the matters submitted to a vote of the Company’s stockholders at the special meeting are as follows: 1. The Extension Proposal The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations”

Estrella Immunopharma, Inc. shareholders approved The Director Election Proposal The stockholders re-elected Mr. Weston Twigg as Class I director of the Company to serve three-year term till the 2025 annual meeting of stockholders or until his successor is elected and qualified. at the 2022-12-22 meeting.

“On December 22, 2022, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2022 annual meeting of stockholders (the “Special Meeting”). On November 30, 2022, the record date for the Special Meeting, there were 5,849,700 shares of common stock of the Company entitled to be voted at the Special Meeting, approximately 74.89% of which were represented in person or by proxy at the special meeting. The final results for each of the matters submitted to a vote of the Company’s stockholders at the special meeting are as follows: 1. The Extension Proposal The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations”

Estrella Immunopharma, Inc. shareholders approved The Trust Amendment Proposal The stockholders approved the proposal to amend the Investment Management Trust Agreement, dated July 14, 2021, by and between the Company and Wilmington Trust, National Association, acting as trustee, to extend the liquidation date from January 19, 2023 to July 19, 2023 at the 2022-12-22 meeting.

“On December 22, 2022, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2022 annual meeting of stockholders (the “Special Meeting”). On November 30, 2022, the record date for the Special Meeting, there were 5,849,700 shares of common stock of the Company entitled to be voted at the Special Meeting, approximately 74.89% of which were represented in person or by proxy at the special meeting. The final results for each of the matters submitted to a vote of the Company’s stockholders at the special meeting are as follows: 1. The Extension Proposal The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations”

Estrella Immunopharma, Inc. shareholders approved The Extension Proposal The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the boa at the 2022-12-22 meeting.

“On December 22, 2022, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2022 annual meeting of stockholders (the “Special Meeting”). On November 30, 2022, the record date for the Special Meeting, there were 5,849,700 shares of common stock of the Company entitled to be voted at the Special Meeting, approximately 74.89% of which were represented in person or by proxy at the special meeting. The final results for each of the matters submitted to a vote of the Company’s stockholders at the special meeting are as follows: 1. The Extension Proposal The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations”

James Long was appointed as Director at Estrella Immunopharma, Inc..

“Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.”

Tao Jiang was appointed as Director at Estrella Immunopharma, Inc..

“Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.”

Weston Twigg was appointed as Director at Estrella Immunopharma, Inc..

“Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.”